Aldrin Quickview (CASRN 309-00-2)

Status of Data for Aldrin

File First On-Line: 03/31/1987; Last Significant Revision: 01/01/1991

Category (section)	Status	Last Revised
Oral RfD Assessment	On-line	03/01/1988
Inhalation RfC Assessment	No data
Carcinogenicity Assessment	On-line	07/01/1993

Synonyms

309-00-2 Aldrex Aldrin Aldrite Aldrosol

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1 alpha, 4 alpha, 4a beta, 5 alpha, 8 alpha, 8a beta)- 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro- Drinox ENT 15,949 more...

Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect	Point of Departure*	UF	MF	RfD
Liver toxicity	LOAEL : 0.025 mg/kg-day	1000	1	3 x10-5 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

• Principal and Supporting Studies (Oral RfD)
  • Rat chronic feeding study, Fitzhugh et al., 1964
• Confidence in the Oral RfD
  • Study -- Medium
  • Database -- Medium
  • RfD -- Medium

Top of page

---

Reference Concentration for Chronic Inhalation Exposure (RfC)

Not Assessed under the IRIS Program.

Top of page

Carcinogenicity Assessment for Lifetime Exposure

• Weight-of-Evidence Characterization
  • B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals)
• Weight-of-Evidence Narrative:
  • Orally administered aldrin produced significant increases in tumor responses in three different strains of mice in both males and females. Tumor induction has been observed for structurally related chemicals, including dieldrin, a metabolite.
  • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

---

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

Oral Slope Factor(s)	Extrapolation Method
1.7 x101 per mg/kg-day	Linearized multistage procedure, extra risk

Drinking Water Unit Risks
4.9x10-4 per ug/L

Risk Level	Concentration
E-4 (1 in 10,000)	2x10-1 ug/L
E-5 (1 in 100,000)	2x10-2 ug/L
E-6 (1 in 1,000,000)	2x10-3 ug/L

• Dose-Response Data (Carcinogenicity, Oral Exposure)
  • Tumor Type: Liver carcinoma
  • Test Species: Mouse/C3H (Davis); mouse/B6C3F1, male (NCI)
  • Route: Oral, Drin
  • Reference: Davis, 1965, NCI, 1978

---

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

Inhalation Unit Risk(s)	Extrapolation Method
4.9 x10-3 per ug/m3	Linearized multistage procedure, extra risk

Inhalation Concentrations at Specified Risk Levels

Risk Level	Concentration
E-4 (1 in 10,000)	2.x10-2 ug/m3
E-5 (1 in 100,000)	2.x10-3 ug/m3
E-6 (1 in 1,000,000)	2.x10-4 ug/m3

• Dose-Response Data (Carcinogenicity, Inhalation Exposure)
  • Tumor Type: Liver carcinoma
  • Test Species: Mouse/C3H (Davis); mouse/B6C3F1, male (NCI)
  • Route: Oral, Diet
  • Reference: Davis, 1965, NCI, 1978